1 Kauferstein, S., Kiehne, N., Neumann, T., Pitschner, H. F. & Bratzke, H. Plötzlicher Herztod bei jungen Menschen durch kardiale Gendefekte. Dtsch Arztebl 106, 41–47 (2009).
2 Universitätsspital Zürich. Online verfügbar unter
https://www.usz.ch/krankheit/ploetzlicher-herztod/; letzter Zugriff: 24.11.2022.
3 Weintraub, W. S. et al. Prediction of Long-Term Mortality After Percutaneous Coronary Intervention in Older Adults Results From the National Cardiovascular Data Registry. Circulation 125, 1501–1510 (2012).
4 Solomon, S. D. et al. Sudden Death in Patients with Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both. N Engl J Med 352, 2581–2588 (2005).
5 Hohnloser, S. H. et al. Prophylactic Use of an Implantable Cardioverter-Defibrillator after Acute Myocardial Infarction. NEJM 351, 2481–2488 (2004).
6 Steinbeck, G. et al. Defibrillator Implantation Early after Myocardial Infarction. NEJM 15, 1427–1436 (2009).
7 Kadish, A. et al. Patients With Recently Diagnosed Nonischemic Cardiomyopathy Benefit From Implantable Cardioverter-Defibrillators. J Am Coll Cardiol 47, 2477–2482 (2006).
8 Zeppenfeld, K. et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 1–130 (2022) doi.10.1093/eurheartj/ehac262.
9 McDonagh, T. A. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal vol. 42 3599–3726 Preprint at
https://doi.org/10.1093/eurheartj/ehab368 (2021).
10 Garcia, R. et al. Wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: The WEARIT-France cohort study. Europace 23, 73–81 (2021).
11 Odeneg, T. et al. Indications for and outcome in patients with the wearable cardioverter-defibrillator in a nurse-based training programme: results of the Austrian WCD Registry. European Journal of Cardiovascular Nursing 18, 75–83 (2019).
12 Wäßnig, N. K. et al. Experience with the wearable cardioverter-defibrillator in patients at high risk for sudden cardiac death. Circulation 134, 635–643 (2016).
13 Kutyifa, V. et al. Use of the wearable cardioverter defibrillator in high-risk cardiac patients data from the prospective registry of patients using the wearable cardioverter defibrillator (WEARIT-II registry). Circulation 132, 1613–1619 (2015).
14 Kovacs, B. et al. Use of the wearable cardioverter-defibrillator – the Swiss experience. Swiss Med Wkly 150, w20343 (2020).
15 Mueller-Leisse, J. et al. Extended follow-up after wearable cardioverter-defibrillator period: the PROLONG-II study. ESC Heart Fail 8, 5142–5148 (2021).
16 Halkin, A. et al. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: The CADILLAC risk score. J Am Coll Cardiol 45, 1397–1405 (2005).
17 Zishiri, E. T. et al. Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter defibrillator. Circ Arrhythm Electrophysiol 6, 117–128 (2013).
18 Adabag, A. S., Therneau, T. M., Gersh, B. J., Weston, S. A. & Roger, V. L. Sudden Death After Myocardial Infarction. JAMA vol. 300,
www.jama.com (2008).
19 Packer, M. et al. The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure. N Engl J Med 334, 1349–1355 (1996).
20 Deneke, T. et al. Kommentar zu den ESC-Leitlinien 2015 „Ventrikuläre Arrhythmien und Prävention des plötzlichen Herztodes“. Kardiologe 11, 27–43 (2017).
21 Priori, S. G. et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). European Heart Journal vol. 36 2793–2867 Preprint at https://doi.org/10.1093/eurheartj/ehv316 (2015).
22 Al-Khatib, S. M. et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary. Circulation 138, e210–e271 (2018).